Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LMP7 Double Nickase Plasmid (h): sc-402382-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LMP7 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LMP7 Double Nickase Plasmid (h) and LMP7 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PSMB8. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LMP7 Antibody (A-12): sc-365699
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LMP7 Double Nickase Plasmid (h) | sc-402382-NIC | 20 µg | $410.00 | |||
LMP7 Double Nickase Plasmid (h2) | sc-402382-NIC-2 | 20 µg | $410.00 |
Human PSMB8 encodes LMP7, an interferon-γ–inducible catalytic β subunit of the immunoproteasome that replaces the constitutive proteasome subunit PSMB5 to alter proteolytic specificity. LMP7 contributes to ubiquitin–proteasome system function by shaping peptide generation for MHC class I antigen processing, thereby influencing adaptive immune surveillance and inflammatory signaling. Remodeling of proteasome activity through PSMB8 induction is linked to immune cell differentiation and stress responses, and dysregulation of immunoproteasome composition has been associated with chronic inflammatory states and autoimmunity. Pathogenic variation in PSMB8 has also been connected to autoinflammatory phenotypes characterized by aberrant cytokine signaling and impaired proteostasis.
LMP7 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PSMB8 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PSMB8. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PSMB8 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PSMB8-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.